The MILAN platform belongs to LISCO, the KU Leuven Institute for Single Cell Omics. MILAN – Multiple Iterative Labeling by Antibody Neodeposition – is an automated immunofluorescence-based multiplex platform for advanced biomarker research at the single-cell level.
I was asked to screen pharma and biotech industry interest in the MILAN platform as a service for advanced biomarker research. Through Voice of the Customer interviews and additional desk research, I mapped market interest, minimal viable technical requirements and the competitive service landscape.
Finally, I estimated the global market potential, suggested pricing and developed potential business models.
